We've detected an Ad Blocker in your browser.

Please disable or pause the Ad Blocker and refresh the page to be able to register and access the website normally.

Menu

24–25 March



REGISTER FREE

Watch Now On-demand

LOG IN

Please enter your email address

Having trouble logging in? Please email info@radcliffe-group.com

validation result

Please choose one of the options shown

Please enter your registration lead id

Please enter your registration session id

Please enter your successful log-in count

feed resp param id

Please choose one of the options shown

A global virtual event dedicated to the latest cardiorenal metabolic disease treatment strategies to support better patient outcomes

Overview

KDIGO and Translational Medicine Academy (TMA) in partnership with Radcliffe Cardiology are delighted to introduce e-SPACE Cardio-Renal-Metabolic 2023 to be held 24–25 March.

e-SPACE Cardio-Renal-Metabolic 2023 will deliver best-in-class free-to-access virtual education. Bringing together thought-leaders from across the globe, e-SPACE Cardio-Renal-Metabolic 2023 will both optimise geographical reach whilst delivering both global and regional insight.

A thoughtfully curated programme will support the exploration of how leading experts, in cardiology, nephrology, and diabetology, are treating the interrelated diseases.

Course leadership Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE), Dr Javed Butler (Baylor Scott and White Research Institute, Texas, US), Prof Antonio Ceriello (IRCCS MultiMedica, Milan, IT), Prof Tara I. Chang (Stanford University, California, US), Prof Ian de Boer (University of Washington, Washington, US), Prof Peter Rossing (University of Copenhagen, Copenhagen, DK) and Prof Shelley Zieroth (St. Boniface Hospital, Winnipeg, CA) will lead an interactive programme of plenary sessions, meet the experts, case discussions and industry sponsored sessions focusing on the patient journey.

Following on from the success of e-SPACE Heart Failure 2022, e-SPACE Cardio-Renal-Metabolic 2023 will again bring together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.

Underpinned by this combined expertise in educational content and delivery, and led by an international faculty of global standing, e-SPACE Cardio-Renal-Metabolic 2023 promises to be the widest reaching and most engaging to date.

REGISTER FREE NOW

REGISTER NOW

Register Now

This live conference starts in:

DAYS
:

HOURS
:

MINS
:

SECS

Course Leadership

Prof Stefan Anker
Prof Stefan Anker

CHAIR
Charité Campus Virchow-Klinikum, Berlin, DE

Prof Stefan Anker studied medicine at Charité Medical School of Humboldt-University Berlin, Germany from 1987 to 1993. He went on to complete his PhD at the National Heart and Lung Institute of Imperial College London, United Kingdom, in 1998. Since then, he has had teaching appointments in several countries including the UK, Germany, Australia and Italy.
He has worked as a Junior Professor and then as Professor for Charité Campus Virchow-Klinikum since 2002. He is a member of and serves on the Boards of several academic organizations, including the Board of the Heart Failure Association of the European Society of Cardiology and the Editorial Board of the Journal of Cachexia, Sarcopenia and Muscle (SCWD). He is also a member of the German Centre for Cardiovascular Research (DZHK).

More info

Less info

Dr Javed Butler
Dr Javed Butler

CO-CHAIR
Baylor Scott and White Research Institute, Texas, US

Dr Javed Butler is Professor and Chair of the Department of Medicine at University of Mississippi Medical Center in Jackson Mississippi, and also Patrick H Lehan Chair of Cardiovascular Research. He is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He has authored more than 900 peer-reviewed publications. Previously, he was Director of the Division of Cardiovascular Medicine and Co-director of the Heart Institute at State University of New York (SUNY) Stony Brook University.

More info

Less info

 Prof Antonio Ceriello
Prof Antonio Ceriello

CHAIR
IRCCS MultiMedica, Milan, IT

Prof Antonio Ceriello is Head of Diabetes Department at IRCCS MultiMedica, Milan, IT. Prof Ceriello has chaired the International Diabetes Federation (IDF) committee for the development in 2008, and in the 2011 for the update of “Guideline for Management of Postmeal Glucose ”. Currently, he is the President of the European Association for the Study of Diabetes (EASD) Study Group on “Diabetes and CardiovascularDiseases”.

More info

Less info

Prof Tara I. Chang
Prof Tara I. Chang

CO-CHAIR
Stanford University, California, US

Prof Tara I. Chang, is an Associate Professor of Medicine and Chief of the Division of Nephrology at Stanford University, California, US. Her research program focuses on hypertension and cardiovascular outcomes in CKD. Prof Chang is a certified Hypertension Specialist and is part of the Stanford Hypertension Center which provides innovative care for patients with severe hypertension.

More info

Less info

Prof Ian de Boer
Prof Ian de Boer

CHAIR
University of Washington, Washington, US

Prof Ian de Boer is a Nephrologist, Professor of Medicine, and Adjunct Professor of Epidemiology at the University of Washington, Washington, US. His research focuses on the metabolic causes and consequences of chronic kidney disease. Prof de Boer focuses on the development, progression, and complications of diabetic kidney disease, and the role of impaired mineral metabolism in the pathogenesis of chronic kidney disease and cardiovascular diseases.

More info

Less info

Prof Peter Rossing
Prof Peter Rossing

CHAIR
University of Copenhagen, Copenhagen, DK

Prof Peter Rossing is a clinician researcher devoted to complications in diabetes with focus on renal and cardiovascular complications. He obtained a specialist degree in internal medicine and endocrinology 2004. Since 2007 he has been a chief physician and manager of the Steno Diabetes Center research team dedicated to the research of micro-and macrovascular complications of diabetes. And since 2012, Professor in diabetic angiopathy at University of Copenhagen, Copenhagen, DK. He is coordinator of the EU FP7 project PRIORITY aiming to test if urinary proteomics can be used to stratify prevention of renal complications in type 2 diabetes, and the Novo Nordisk Foundation grant PROTON aiming at personalising prevention of diabetic nephropathy.

More info

Less info

Prof Shelley Zieroth
Prof Shelley Zieroth

CO-CHAIR
St. Boniface Hospital, Winnipeg, CA

Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St. Boniface Hospital in Winnipeg, CA. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba. She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Immediate Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She serves as Co-Chair of Canada’s largest annual heart failure meeting, HF Update and serves as Scientific Planning Committee Chair for the Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society. She is currently President-elect of the Federation of Medical Women of Canada. Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review

More info

Less info

Faculty

Prof William Abraham

Ohio State University College of Medicine, Ohio, US

Dr Suzanne Arnold

University of Missouri Kansas City, Missouri, US

Dr John Atherton

Royal Brisbane and Women’s Hospital, Brisbane, AU

Dr Nisha Bansal

University of Washington, Washington, US

Prof Sunil Bhandari

Royal College of Physicians of Edinburgh, Edinburgh, UK

Prof Michael Böhm

Saarland University Hospital, Homburg, DE

Dr A Enrique Caballero

Harvard Medical School, Massachusetts, US

Dr Maria Luiza Caramori

Cleveland Clinic, Ohio, US

Dr Kerri L Cavanaugh

Vanderbilt University Medical Center, Tennessee, US

Prof Vijay Chopra

Max Super Specialty Hospital, New Delhi, IN

Prof John Cleland

University of Glasgow, Glasgow, UK

Prof Andrew Coats

Heart Research Institute, Newtown, AU

Prof Melanie Davies

Leicester Diabetes Centre, Leicester, UK

Dr Cynthia Delgado

University of California, California, US

Prof Wolfram Doehner

Charité – Universitätsmedizin Berlin, Berlin, DE

Prof Gerasimos Filippatos

National and Kapodistrian University of Athens, Athens, GR

Prof Paola Fioretto

University of Padova, Padua, IT

Dr Marat Fudim

Duke University, North Carolina, US

Prof Hiddo Lambers Heerspink

University Medical Center Groningen, Groningen, NL

Dr Mehriban Isgandar

Azerbaijan Medical University, Baku, AZ

Dr Areef Ishani

Minneapolis VA Health Care System, Minnesota, US

Prof Michel Jadoul

Université catholique de Louvain, Ottignies-Louvain-la-Neuve, BE

Prof Ewa Jankowska

Wrocław Medical University, Wrocław, PL

Prof Meg Jardine

University of Sydney, Camperdown, AU

Prof Mitja Lainscak

University of Ljubljana, Ljubljana, SI

Dr Tammy Lyn Kindel

Medical College of Wisconsin, Wisconsin, US

Prof Carel le Roux

University College Dublin, Dublin, IE

Dr Edgar V Lerma

University of Illinois, Illinois, US

Dr Ildiko Lingvay

UT Southwestern Medical Center, Texas, US

Prof Jolanta Małyszko

Medical University of Warsaw, Warsaw, PL

Dr Kieran McCafferty

Queen Mary University of London, London, UK

Prof Iain Macdougall

King's College Hospital, London, UK

Prof John McMurray

University of Glasgow, Glasgow, UK

Prof Alexandre Mebazaa

Lariboisière Hospital AP-HP, Paris, FR

Dr Erin D Michos

The Johns Hopkins University School of Medicine, Maryland, US

Prof Wilfried Mullens

Hospital Oost-Limburg, Genk, BE

Dr Sankar D Navaneethan

Baylor College of Medicine, Texas, US

Dr Milton Packer

Baylor University Medical Center, Texas, US

Dr Ambarish Pandey

University of Texas Southwestern Medical Center, Texas, US

Prof Giuseppe Paolisso

University of Campania Luigi Vanvitelli, Caserta, IT

Prof Fausto Pinto

Santa Maria University Hospital, Lisbon, PT

Prof Francesco Prattichizzo

IRCCS MultiMedica, Milan, IT

Dr Janani Rangaswami

George Washington University School of Medicine and Health Sciences, Washington, US

Prof Giuseppe Rosano

St George's University of London, London, UK

Dr Gianluigi Savarese

Karolinska Institute, Stockholm, SE

Prof Petar Seferović

Belgrade University, Belgrade, RS

Dr María José Soler

Vall d'Hebron University Hospital, Barcelona, ES

Dr John A Spertus

UMKC School of Medicine, Missouri, US

Prof Eberhard Standl

Munich Diabetes Research Group, Munich, DE

Dr Manjula Kurella Tamura

Stanford University, California, US

Prof Pinar Topsever

Acıbadem University School of Medicine, Istanbul, TR

Prof Apostolos G Tsapas

Aristotle University of Thessaloniki, Thessaloniki, GR

Dr Muthiah Vaduganathan

Brigham and Women’s Hospital, Massachusetts, US

Prof Luc Van Gaal

University of Antwerp, Antwerp, BE

Dr Daniël van Raalte

VU University Medical Center, Amsterdam, NL

Dr Orly Vardeny

University of Minnesota, Minnesota, US

Prof Stephan von Haehling

University Medicine Göttingen, Göttingen, DE

Prof Adriaan Voors

University Medical Center Groningen, Groningen, NL

Prof Christoph Wanner

University of Würzburg, Würzburg, DE

Dr Matthew R Weir

University of Maryland, Maryland, US

Prof David Wheeler

University College London, London, UK

Prof Christopher Wilcox

Georgetown University, Washington D.C., US

Dr Faiez Zannad

Academic Hospital (CHU), Nancy, FR

Register now

Programme

(Please note this programme is subject to change)

VIEW PROGRAMME (PDF)
Friday, 24 March 2023 (Day 1)
Bangkok Time (ICT)
Paris Time (CET)
Rio Time (BRT)
Part 1
15:00-16:00
09:00-10:00
05:00-06:00
Plenary session 1 – HFpEF

Chairs – Andrew Coats, AU and Giuseppe Rosano, UK
• Epidemiology and clinical features – Giuseppe Rosano, UK
• Diabetes as a key risk factor for HFpEF – Eberhard Standl, DE
• HFpEF and chronic kidney disease: one and the same? – María José Soler, ES
• Management with new drugs and devices – Stefan Anker, DE
• Panel discussion

Break
16:10-16:50
10:10-10:50
06:10-06:50
Satellite symposium
Break
17:00-18:00
11:00-12:00
07:00-08:00
Plenary session 2 – SGLT2 updates

Chairs – Andrew Coats, AU and Hiddo Heerspink, NL
• Focus on diabetology – Antonio Ceriello, IT
• Focus on cardiology – Gianluigi Savarese, SE
• Focus on nephrology – Christoph Wanner, DE
• Panel discussion

Part 2
20:20-20:50
14:20-14:50
10:20-10:50
Meet the expert
Break
21:00-22:00
15:00-16:00
11:00-12:00
Plenary session 3 – Weight management in CRM disease

Chairs – Luc Van Gaal, BE and Wolfram Doehner, DE
• Obesity and CRM disease: epidemiology and pathophysiology – Milton Packer, US
• Weight control in diabetes: new strategies and outcomes – Carel le Roux, IE
• Bariatric surgery – Tammy L Kindel, US
• Weight control therapies: effects on BP, kidney and CV outcomes – Ildiko Lingvay, US
• Panel discussion

Break
22:10-22:40
16:10-16:40
12:10-12:40
Meet the expert
Break
23:00-00:00
17:00-18:00
13:00-14:00
Plenary session 4 – Guidelines implementation for acutely ill patients

Chairs – Stephan von Haehling, DE and Mehriban Isgandar, AZ
• Uptitrating the foundational HF therapies – Alexandre Mebazaa, FR
• Where to start: is the hospital the best place? – Adriaan Voors, NL
• What can telehealth options provide? – Marat Fudim, US
• What about cost issues? – Vijay Chopra, IN
• Panel discussion

Part 3
01:00-02:00
19:00-20:00
15:00-16:00
Plenary session 5 – Mineralocorticoids antagonists in CRM disease

Chairs – Javed Butler, US and Sunil Bhandari, UK
• Steroidal and nonsteroidal MRA structure and function – all the same? – Edgar V Lerma, US
• Antihypertensive effects of MRAs – Faiez Zannad, FR
• Kidney effects of MRAs – Janani Rangaswami, US
• MRAs for prevention and treatment of heart failure – Gerasimos Filippatos, GR
• Panel discussion

Break
02:10-02:50
20:10-20:50
16:10-16:50
Meet the expert
Break
03:00-04:00
21:00-22:00
17:00-18:00
Plenary session 6 – Diuretics: old drugs, new data, new approaches

Chair – Nisha Bansal, US
• Return to the nephron - mechanism of action of diuretics – Christopher Wilcox, US
• Diuretics to treat acute decompensated heart failure – Wilfried Mullens, BE
• Diuretics to treat hypertension – Areef Ishani, US
• Can devices therapy make a difference? – William Abraham, US
• Panel discussion

Saturday, 25 March 2023 (Day 2)
Bangkok Time (ICT)
Paris Time (CET)
Rio Time (BRT)
Part 4
15:00-16:00
09:00-10:00
05:00-06:00
Plenary session 7 – CRM drug management in patients with low eGFR and type 2 diabetes

Chairs – John Atherton, AU and Petar Seferovic, RS
• When should we STOP ACEi? – John Cleland, UK
• Blood pressure targets and agents for patients with very low eGFR – Michael Böhm, DE
• Practical considerations for use of SGLT2i with low eGFR – Meg Jardine, AU
• GLP1RA – just what’s needed for patients with CKD? – Daniël van Raalte, NL
• Panel discussion

Break
16:10-16:50
10:10-10:50
06:10-06:50
Satellite symposium
Break
17:00-18:00
11:00-12:00
07:00-08:00
Plenary session 8 – Diabetes and cardio-renal disease: the relevance of early treatment with the right drug

Chairs – Peter Rossing, DK and Antonio Ceriello, IT
• The legacy effect of early intensive management in diabetes – Francesco Prattichizzo, IT
• The evidence in favour of an early use of SGLT-2i and GLP-1RA – Apostolos G Tsapas, GR
• The new ADA-EASD consensus – Melanie Davies, UK
• Heart failure is the ultimate problem: how to manage? – John McMurray, UK
• Panel discussion

Part 5
20:20-20:50
14:20-14:50
10:20-10:50
Meet the expert / Case discussion
Break
21:00-22:00
15:00-16:00
11:00-12:00
Plenary session 9 – Managing “metals”

Chairs – Javed Butler, US and Shelley Zieroth, CA
• Anaemia in CRM disease: update 2023 – Iain Macdougall, UK
• Iron deficiency in CRM disease: update 2023 – John Cleland, UK
• Hyperkalemia in CRM disease: update 2023 – Matthew R Weir, US
• Potassium management with finerenone or SGLT2i – Paola Fioretto, IT
• Panel discussion

Break
22:10-22:50
16:10-16:50
12:10-12:50
Satellite symposium
Break
23:00-00:00
17:00-18:00
13:00-14:00
Plenary session 10 – Management of diabetes with kidney disease

Chairs – Peter Rossing, DK and Sankar Navaneethan, US
• How to manage glucose – Maria Luiza Caramori, US
• How to manage kidney risk – Ian de Boer, US
• How to handle CV risk – Erin D Michos, US
• How to bring it together – Peter Rossing, DK
• Panel discussion

Part 6
01:00-02:00
19:00-20:00
15:00-16:00
Plenary session 11 – Managing frail and elderly patients

Chairs – Mitja Lainscak, SI and Fausto Pinto, PT
• Cachexia, sarcopenia, frailty and aging: update 2023 – Mitja Lainscak, SI
• The diabetologist’s point of view – A Enrique Caballero, US
• The nephrologist’s point of view – Cynthia Delgado, US
• The cardiologist’s point of view – Ambarish Pandey, US
• Panel discussion

Break
02:10-02:50
20:10-20:50
16:10-16:50
Meet the expert
Break
03:00-04:00
21:00-22:00
17:00-18:00
Plenary session 12 – Managing end-stage disease: focus on QoL

Chairs – Kerri L Cavanaugh, US and Fausto Pinto, PT
• QoL assessment in CRM disease: update 2023 – John A Spertus, US
• The diabetologist’s point of view – Giuseppe Paolisso, IT
• The nephrologist’s point of view – Manjula Kurella Tamura, US
• The cardiologist’s point of view – Suzanne V Arnold, US
• Panel discussion

Target Audience

  • Cardiologists
  • Nephrologists
  • Diabetologists
  • General Practitioners (GPs)
  • HF Specialists
  • Nurses, Pharmacists, and other Allied Healthcare Professionals

Learning Objectives

  • Review the burden of diabetes, kidney disease and heart failure including morbidity, excess mortality, and reduced quality of life affecting individuals around the world
  • Describe the complexity and interlink between the three conditions
  • Discuss existing guidelines and best approaches for screening patients
  • Review evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity including SLGT2i, GLP-1RA, new non-steroidal mineralocorticoid receptor antagonists and other emerging therapies
  • Foster cross-collaboration between other cardiorenal / metabolic specialists and primary care physicians and allied health care professionals in order to improve patients outcomes

Sponsors:

Gold

Bronze


If you’re interested in becoming an educational partner or sponsor at this event, please contact sales@radcliffe-group.com

About KDIGO

KDIGO is a global organisation developing and implementing evidence-based clinical practice guidelines in kidney disease. It is an independent, volunteer-led, self-managed foundation incorporated in Belgium and accountable to the public and the patients it serves.

KDIGO’s mission is to improve the care and outcomes of patients with kidney disease worldwide through the development and implementation of global clinical practice guidelines.

For more information on KDIGO, please visit https://kdigo.org.

About Translational Medicine Academy

Our ambition at the Translational Medicine Academy® (TMA) is to bring medical findings from bench to bedside and into the working lives of physicians and the care of patients. In seeking to improve therapeutic approaches, TMA works with its International Scientific Advisory Board on Critical Mission Areas® of public health importance in domains where there are educational shortcomings among physicians and unmet healthcare needs among patients.

Gathered around a Scientific Advisory Board of experts, the Translational Medicine Academy is an international non-profit Foundation with headquarter in Basel, and offices in Paris, and the US. TMA’s funding includes private donations from individuals and educational grants from governments, non-governmental organizations and corporations.

For more information on TMA, please visit www.tmacademy.org.

About Radcliffe Cardiology

We are Radcliffe, a knowledge network for the cardiovascular community.

We’re here to bring cardiovascular knowledge, insight and innovation to life for clinicians around the world, using our communications and creative expertise, our platforms and connections across the community to help transform theory into practice faster and more effectively.

We bring medical knowledge to life

From great science writing and smart journal editing, the curation of evidence based and peer-reviewed content, to engaging new formats that cut through the noise, we believe that communication is at the heart of great healthcare.

Our work is underpinned by 3 core principles:


Our promise is that we’ll equip you with the latest knowledge and skills you need, to do the best for your patients.

For more information on Radcliffe Cardiology, please visit www.radcliffecardiology.com.

Please contact events@radcliffe-group.com should you have any queries.